Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial
UBT251 is being jointly developed by United Bio-Technology and Novo Nordisk under a March 2025 agreement.
25 February 2026
25 February 2026
UBT251 is being jointly developed by United Bio-Technology and Novo Nordisk under a March 2025 agreement.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.